<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576988</url>
  </required_header>
  <id_info>
    <org_study_id>A011-11</org_study_id>
    <nct_id>NCT04576988</nct_id>
  </id_info>
  <brief_title>A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (STELLAR)</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the efficacy and safety of sotatercept treatment&#xD;
      (plus background PAH therapy) versus placebo (plus background PAH therapy) at 24 weeks in&#xD;
      adults with PAH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group&#xD;
      study in subjects with symptomatic Pulmonary Arterial Hypertension (PAH) who present with&#xD;
      idiopathic or heritable PAH, PAH associated with connective tissue diseases (CTD), drug or&#xD;
      toxin induced, post shunt correction PAH, or PAH presenting at least 1 year following the&#xD;
      correction of congenital heart defects (CHDs), and currently on background PAH therapy.&#xD;
&#xD;
      The primary efficacy endpoint of the study is exercise capacity, as measured by the 6-minute&#xD;
      walk distance (6MWD) measured at 24 week following initiation of treatment.&#xD;
&#xD;
      Approximately 284 participants will be enrolled and randomized 1:1 to receive either&#xD;
      sotatercept or placebo on the background of stable standard-of-care PAH mediation. Study&#xD;
      duration will be approximately 2 years A stratified Wilcoxon test will be used for analysis&#xD;
      of the primary endpoint, with appropriate imputation for missing data, as detailed in the&#xD;
      Statistical Analysis Plan. An unblinded, external, independent Data Monitoring Committee&#xD;
      (DMC) will monitor participant safety throughout the course of the study. Participants&#xD;
      completing this study will be eligible to receive sotatercept in a separate, open-label&#xD;
      extension study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized to one of two treatment arms to receive either sotatercept (0.7 mg/kg) by subcutaneous administration once every 3 weeks, or placebo. All participants will be on concurrent, stable background PAH therapy. Randomization will be stratified by baseline WHO Functional Class (Class II or III) and by background PAH therapy (mono/double or triple therapy)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study participants, care providers. Investigators and outcomes assessor will be masked to the study intervention until the final participant complete the 24-week efficacy assessment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 6MWD.</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants achieving the multicomponent improvement endpoint, consisting of all of the following:</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
    <description>Improvement in 6MWD (increase ≥ 30 m)&#xD;
Improvement in NT-proBNP (decrease in NT-proBNP ≥ 30%) or maintenance/achievement of NT-proBNP level &lt; 300 ng/L&#xD;
Improvement in WHO FC or maintenance of WHO FC II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pulmonary vascular resistance (PVR).</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who improve in WHO FC.</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NT-proBNP levels.</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death or the first occurrence of any of the following clinical worsening events (TTCW):</measure>
    <time_frame>From initiation of treatment to through study completion, an average of 1 year.</time_frame>
    <description>Worsening-related listing for lung and/or heart transplant&#xD;
Need to initiate rescue therapy with an approved background PAH therapy or the need to increase the dose of infusion prostacyclin by 10% or more&#xD;
Need for atrial septostomy&#xD;
PAH-specific hospitalization (≥ 24 hours)&#xD;
Deterioration of PAH defined by both of the following events occurring at any time, even if they began at different times, as compared to their baseline values:&#xD;
Worsened WHO FC&#xD;
Decrease in 6MWD by ≥ 15% confirmed by 2 tests at least 4 hours apart, but no more than 1 week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who maintain or achieve a low risk score using the simplified French Risk score calculator.</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in EuroQol 5 dimension 5 level (EQ-5D-5L) index score.</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT®).</measure>
    <time_frame>From initiation of treatment to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Sotatercept plus background PAH theraphy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus background PAH therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered (SC) every 21 days plus background PAH therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Sotatercept at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg administered subcutaneously (SC) every 21 days plus background PAH therapy.</description>
    <arm_group_label>Sotatercept plus background PAH theraphy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously (SC) every 21 days plus background PAH therapy.</description>
    <arm_group_label>Placebo plus background PAH therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Documented diagnostic right heart catheterization (RHC) at any time prior to screening&#xD;
             confirming the diagnosis of WHO pulmonary arterial hypertension (PAH) Group 1 in any&#xD;
             of the following subtypes:&#xD;
&#xD;
               -  Idiopathic PAH&#xD;
&#xD;
               -  Heritable PAH&#xD;
&#xD;
               -  Drug/toxin-induced PAH&#xD;
&#xD;
               -  PAH associated with connective tissue disease&#xD;
&#xD;
               -  PAH associated with simple, congenital systemic to pulmonary shunts at least 1&#xD;
                  year following repair&#xD;
&#xD;
          3. Symptomatic PAH classified as WHO Functional Class II or III&#xD;
&#xD;
          4. Baseline RHC performed during the Screening Period documenting a minimum pulmonary&#xD;
             vascular resistance (PVR) of ≥ 5 Wood units (WU)&#xD;
&#xD;
          5. On stable doses of background PAH therapy and diuretics (i.e., patient-specific dose&#xD;
             goal for each therapy already achieved) for at least 90 days prior to screening; for&#xD;
             infusion prostacyclins, dose adjustment within 10% of optimal dose is allowed per&#xD;
             medical practice. Background PAH therapy is defined in Section 7.2&#xD;
&#xD;
          6. 6MWD ≥ 150 and ≤ 500 m repeated twice at screening (measured at least 4 hours apart,&#xD;
             but no longer than 1 week), and both values are within 15% of each other (calculated&#xD;
             from the highest value)&#xD;
&#xD;
          7. Females of childbearing potential must:&#xD;
&#xD;
               -  Have 2 negative urine or serum pregnancy tests as verified by the investigator&#xD;
                  prior to starting study therapy; she must agree to ongoing urine or serum&#xD;
                  pregnancy testing during the study and until 8 weeks after the last dose of the&#xD;
                  study drug&#xD;
&#xD;
               -  If sexually active, have used, and agree to use, highly effective contraception&#xD;
                  without interruption, for at least 28 days prior to starting the investigational&#xD;
                  product, during the study (including dose interruptions), and for 16 weeks (112&#xD;
                  days) after discontinuation of study treatment&#xD;
&#xD;
               -  Refrain from breastfeeding a child or donating blood, eggs, or ovum for the&#xD;
                  duration of the study and for at least 16 weeks (112 days) after the last dose of&#xD;
                  study treatment&#xD;
&#xD;
          8. Male participants must:&#xD;
&#xD;
               -  Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made&#xD;
                  out of natural (animal) membrane (e.g., polyurethane), during sexual contact with&#xD;
                  a pregnant female or a female of childbearing potential while participating in&#xD;
                  the study, during dose interruptions and for at least 16 weeks (112 days)&#xD;
                  following investigational product discontinuation, even if he has undergone a&#xD;
                  successful vasectomy&#xD;
&#xD;
               -  Refrain from donating blood or sperm for the duration of the study and for 16&#xD;
                  weeks (112 days) after the last dose of study treatment&#xD;
&#xD;
          9. Ability to adhere to study visit schedule and understand and comply with all protocol&#xD;
             requirements&#xD;
&#xD;
         10. Ability to understand and provide written informed consent&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of pulmonary hypertension WHO Groups 2, 3, 4, or 5&#xD;
&#xD;
          2. Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus&#xD;
             (HIV)-associated PAH and PAH associated with portal hypertension. Exclusions in PAH&#xD;
             Group I should also include schistosomiasis APAH and pulmonary veno occlusive disease&#xD;
&#xD;
          3. Hemoglobin (Hgb) at screening above gender-specific upper limit of normal (ULN), per&#xD;
             local laboratory test&#xD;
&#xD;
          4. Uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure &gt;&#xD;
             160 mmHg or sitting diastolic blood pressure &gt; 100 mmHg during screening visit after a&#xD;
             period of rest&#xD;
&#xD;
          5. Baseline systolic BP &lt; 90 mmHg at screening&#xD;
&#xD;
          6. Pregnant or breastfeeding women&#xD;
&#xD;
          7. Any of the following clinical laboratory values at the screening visit:&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/m2 (as defined by MDRD&#xD;
                  equation)&#xD;
&#xD;
               -  Serum alanine aminotransferase or aspartate aminotransferase levels &gt; 3 × ULN or&#xD;
                  total bilirubin &gt; 1.5 × ULN&#xD;
&#xD;
          8. Currently enrolled in or have completed any other investigational product study within&#xD;
             30 days for small molecule drugs or within 5 half-lives for biologics prior to the&#xD;
             date of signed informed consent&#xD;
&#xD;
          9. Prior exposure to sotatercept (ACE-011) or luspatercept (ACE 536) and/or excipients or&#xD;
             known allergic reaction to either one&#xD;
&#xD;
         10. Have full or partial pneumonectomy&#xD;
&#xD;
         11. Pulmonary function test (PFT) values of forced vital capacity (FVC) &lt; 60% predicted at&#xD;
             the screening visit or within 6 months prior to the screening visit. If PFT is not&#xD;
             available, a chest CT scan showing no more than mild interstitial lung disease (ILD)&#xD;
             performed at the screening visit or 1 year to it.&#xD;
&#xD;
         12. Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days&#xD;
             prior to the screening visit or planned initiation during the study (participants who&#xD;
             are stable in the maintenance phase of a program and who will continue for the&#xD;
             duration of the study are eligible).&#xD;
&#xD;
         13. History of more than mild obstructive sleep apnea that is untreated&#xD;
&#xD;
         14. Known history of portal hypertension or chronic liver disease, including hepatitis B&#xD;
             and/or hepatitis C (with evidence of recent infection and/or active virus&#xD;
             replication), defined as mild to severe hepatic impairment (Child-Pugh Class A-C)&#xD;
&#xD;
         15. History of restrictive, constrictive or congestive cardiomyopathy&#xD;
&#xD;
         16. History of atrial septostomy within 180 days prior to the screening visit&#xD;
&#xD;
         17. Electrocardiogram (ECG) with Fridericia's corrected QT interval (QTcF) &gt; 500 ms during&#xD;
             the screening period&#xD;
&#xD;
         18. Personal or family history of long QT syndrome (LQTS) or sudden cardiac death&#xD;
&#xD;
         19. Left ventricular ejection fraction &lt; 45% on historical echocardiogram within 6 months&#xD;
             prior to the screening visit or pulmonary capillary wedge pressure &gt; 15 mmHg as&#xD;
             determined in the Screening Period RHC&#xD;
&#xD;
         20. Any symptomatic coronary disease events&quot; within 6 months (prior myocardial infarction,&#xD;
             percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac&#xD;
             anginal chest pain) within 6 months of the screening visit. Note: Anginal pain can be&#xD;
             ignored as an exclusion criterion if coronary angiography shows no obstructions.&#xD;
&#xD;
         21. Cerebrovascular accident within 3 months prior to the screening visit&#xD;
&#xD;
         22. Acutely decompensated heart failure within 30 days prior to the screening visit, as&#xD;
             per investigator assessment&#xD;
&#xD;
         23. Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular&#xD;
             disease, mitral stenosis and more than mild aortic valve stenosis&#xD;
&#xD;
         24. Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine,&#xD;
             vasopressin) within 30 days prior to the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janethe de Oliveira Pena, MD</last_name>
    <role>Study Director</role>
    <affiliation>Acceleron Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Manger</last_name>
    <phone>617-649-9200</phone>
    <email>Clinicaltrials011@acceleronpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nidhi Samaraweera</last_name>
      <email>nidhi-research@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephen Fuller</last_name>
      <email>stephen-research@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremy Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates P.A.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-2158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LiYi Fu</last_name>
      <email>L.Fu@pulmonaryassociates.com</email>
    </contact>
    <investigator>
      <last_name>David Baratz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Martinez-Ceren</last_name>
      <email>pmm001@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>David Poch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanpreet Kaur</last_name>
      <email>axkaur@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Anastasiya Ivanko</last_name>
      <email>aiivanko@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Namita Sood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Stenftennagel</last_name>
      <email>alexis.stenftennagel@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>David Badesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>23007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Quinones</last_name>
      <email>anaquinones@mfa.gwu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sara Smith</last_name>
      <email>sarsmith@mfa.gwu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mardi Gomberg-Maitland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Grube</last_name>
      <email>klgrube@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo Restrepo-Jaramillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Halaby</last_name>
      <phone>404-712-7458</phone>
      <email>tracy.halaby@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mitzi Near</last_name>
      <phone>404-727-2011</phone>
      <email>mnear@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Micah Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Boccardi</last_name>
      <email>lboccardi@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie A. Spikes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hays</last_name>
      <email>mhays@tuftsmedicalcenter.org</email>
    </contact>
    <contact_backup>
      <last_name>Abigail Pires</last_name>
      <email>apires@tuftsmedicalcenter.org</email>
    </contact_backup>
    <investigator>
      <last_name>Harrison Farber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mallory Newsted</last_name>
      <email>mallorth@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Moles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Newton-Lovato</last_name>
      <email>elovato@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Heuerman</last_name>
      <email>sheuerman@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Murali Chakinala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-5990</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jena Sweeter</last_name>
      <email>jenea.sweeter@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Tammy Wichman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renown Institute for Heart &amp; Vascular Health</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa English</last_name>
      <email>lisa.english@renown.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Rowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine-New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn Bastert</last_name>
      <email>kab4007@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Evelyn Horn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Mintz</last_name>
      <email>andrew_mintz@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>James R White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Womack</last_name>
      <email>sam.womack@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Terry Fortin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>41076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Anderson</last_name>
      <email>ander5ja@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Elwing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Carl and Edyth Linder Center for Research at the Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Robertson</last_name>
      <email>roxanne.robertson@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Peter Engel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wexner Medical Center at the Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Lever</last_name>
      <email>kimberly.lever@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Veronica Franco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Palmisciano</last_name>
      <email>apalmisciano@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>James Klinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Callender</last_name>
      <email>rcallender@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Ann Saulino</last_name>
      <email>asaulino@houstonmethodist.org</email>
    </contact_backup>
    <investigator>
      <last_name>Zeenat Safdar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carri McKnight</last_name>
      <email>cjmcknig@sentara.com</email>
    </contact>
    <contact_backup>
      <last_name>Melinda Bullivant</last_name>
      <email>mmbulliv@sentara.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Eggert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Médico Dra. De Salvo</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Cecilia</last_name>
      <email>mm.cecilia87@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Antonela Iannazzo</last_name>
      <email>antonelafundacionrespirar@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maria De Salvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Julia Cremona</last_name>
      <email>mcremona@austral.edu.ar</email>
    </contact>
    <contact_backup>
      <last_name>Silvina Giselle</last_name>
      <email>SCrido-ext@austral.edu.ar</email>
    </contact_backup>
    <investigator>
      <last_name>Andrés Atamañuk, MD, Magister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Quilmes SRL</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorgelina Casalá</last_name>
      <email>j.casala@iicquilmes.com.ar</email>
    </contact>
    <investigator>
      <last_name>Andriàn Lescano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial Dr. José María Cullen</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000EOZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Berli</last_name>
      <email>paulaberli89@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Cristian Botta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Rhodes</last_name>
      <email>jessica.rhodes@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Yanfeng Li</last_name>
      <email>yanfeng.li@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Edmond Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annette Pidoux</last_name>
      <email>annette.pidoux@svha.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Karen Brown</last_name>
      <email>karen.brown@svha.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Anne Keogh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marline Squance</last_name>
      <email>Marline.Squance@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Glenn Reeves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Kirkman</last_name>
      <email>helen.kirkman@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>John Wheatley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalee Lawson</last_name>
      <email>natalee.lawson@health.wa.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Xianqin Guo</last_name>
      <email>Xianqin.Guo@health.wa.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Melanie Lavender, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Gayet</last_name>
      <email>frederic.gayet@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Marie De Clippel</last_name>
      <email>marie.de.clippel@erasme.ulb.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Luc Vachiery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Hermans</last_name>
      <email>isabelle.hermans@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Marion Delcroix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oceane Crebier</last_name>
      <email>ocrebier@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie Jondot</last_name>
      <email>mjondot@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno Degano, MBBS, FRACP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bicêtre</name>
      <address>
        <city>Le Kremlin-bicêtre</city>
        <zip>33606</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramdane Meftali</last_name>
      <email>ramdane.meftali@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>David Montani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille Hôpital Cardiologique-Institut Coeur Poumon Service de Cardiologie</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandine Verhaeghe</last_name>
      <email>amandine.verhaeghe@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Pascal De Groote, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Boulhais</last_name>
      <email>m-boulhais@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Arnaud Bourdin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HGRL - CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Godard</last_name>
      <email>elodie.godard@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Regine Valero</last_name>
      <email>regine.valero@chu-nantes.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Delphine Horaeu-Langlard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Zamiti-Smondel</last_name>
      <email>zamiti-smondel.a@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eya Touzri-Setti</last_name>
      <email>touzrisetti.e@chu-nice.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pamela Moceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint Etienne - Hospital</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Souad Bezzeghoud</last_name>
      <email>souad.bezzeghoud@chu-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Carole Chauvet</last_name>
      <email>carole.chauvet@chu-st-etienne.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Bertoletti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Stauder</last_name>
      <email>julien.stauder@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Marianne Riou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sina Heuser</last_name>
      <email>sina.heuser@innere.med.uni-giessen.de</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Lamp</last_name>
      <email>kristin.lamp@innere.med.uni-giessen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ardeschir Ghofrani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristätsklinik und Poliklonik für Innere Medizin I</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berit Heinze</last_name>
      <email>berit.heinze@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Eisenmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Tayler</last_name>
      <email>tayler.susanne@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Marius Hoeper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg gGmbH Zentrum für pulmonale Hypertonie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva-Maria Heier</last_name>
      <email>eva.maria.heier@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Katharina Goller</last_name>
      <email>katharina.goller@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ekkehard Gruenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Davis Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Avital</last_name>
      <email>sharonav1@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yochai Adir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shai Shavit, MD</last_name>
      <email>shai.evenshoshan@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Nava Bechor</last_name>
      <email>nava.bechor@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>David Shitrit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - PPDS</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liora Yehoshua</last_name>
      <email>lioray@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Mordechai Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center - PPDS</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariela Velner</last_name>
      <email>ariela.velner@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Michael Segel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Otago - Hospital</name>
      <address>
        <city>Christchurch</city>
        <state>South Island</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Lumb</last_name>
      <email>tania.lumb@otago.ac.nz</email>
    </contact>
    <investigator>
      <last_name>Lutz Beckert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato District Health Board - Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Tuffery</last_name>
      <email>christine.tuffery@waikatodhb.health.nz</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Hopping</last_name>
      <email>sandra.hopping@waikatodhb.health.nz</email>
    </contact_backup>
    <investigator>
      <last_name>Henry Gallagher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Collis</last_name>
      <email>saracollis@adhb.govt.nz</email>
    </contact>
    <contact_backup>
      <last_name>Maye Hamed</last_name>
      <email>mayeh@adhb.govt.nz</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Whyte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital spec. im. Jana Pawła II Oddziały Kliniczny Chorob Serca i Naczyn z Pododdzialem Intensywnego Nadzrou Kardiologicznego</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalea Wojtowicz</last_name>
      <phone>+48 508292294</phone>
      <email>mwojtow@szpitaljp2.krakow.pl</email>
    </contact>
    <investigator>
      <last_name>Grzegorz Kopec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock Klinika Krazenia Plucnego Chorob Zakrzepowo-Zatotowych Centrum Medyczne Kstalcenia Podyplomowego</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulina Babik</last_name>
      <email>paulina.babik@ecz-otwock.pl</email>
    </contact>
    <investigator>
      <last_name>Adam Torbicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariadna Gonzalez Segovia</last_name>
      <email>ariadna.segovia@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Segovia Cubero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Lopez Rodriquez</last_name>
      <email>solopez@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Cristina Berastegui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Dolores Sanz</last_name>
      <email>mdsanz@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Isabel Blanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Perez</last_name>
      <email>ppv_pilar@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Jesus del Cerro Marin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Ochoa</last_name>
      <email>nuriaochoaparra@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Pilar Escribano Subias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Alonso Lecue</last_name>
      <email>alonsolecue@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jose Manuel Cifrian Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hjärt-lungmedicin och klinisk fysiologi</name>
      <address>
        <city>Uppsala</city>
        <state>Uppsala Lan</state>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Robertsson</last_name>
      <email>louise.robertsson@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Annika Langö</last_name>
      <email>annika.lango@akademiska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Erik Bjorklund, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitets Sjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida Löfgren-Silversparre</last_name>
      <email>ida.lofgren_silversparre@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Sofie Andréen</last_name>
      <email>eva-sofie.andreen@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Clara Hjalmarsson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Zürich, Klinik für Pneumologie</name>
      <address>
        <city>Zürich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Stickel</last_name>
      <email>simone.stickel@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Silvia Ulrich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Clydebank</city>
        <state>West Dunbartonshire</state>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Teyhan</last_name>
      <email>fiona.teyhan@goldenjubilee.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Maureen Connolly</last_name>
      <email>maureen.connolly@gjnh.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alistair Colin Church, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Ochiel</last_name>
      <email>rachel.ochiel@nhs.net</email>
    </contact>
    <investigator>
      <last_name>John Gerry Coghlan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary</keyword>
  <keyword>Hypertension</keyword>
  <keyword>sotatercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Acceleron is committed to sharing clinical trial data following completion of a clinical study. All data provided are de-identified to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared according to the criteria and process to be posted on Acceleron's website.</ipd_access_criteria>
    <ipd_url>http://acceleronpharma.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

